よむ、つかう、まなぶ。
会議資料 (334 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00044.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第66回 12／12）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
（公知申請への該当性に係る企業見解の様式）
要望番号；IV-145
11) Spyridonidis A et al. Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for
Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the
Acute Leukemia Working Party of the EBMT. Hemasphere.2023;7:e812.
12) Srinivasan R et al. Overcoming graft rejection in heavily transfused and allo-immunised
patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell
transplantation. Br J Haematol.2006;133:305-14.
13) Maury S et al. Improved outcome of patients older than 30 years receiving HLA-identical
sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using
fludarabine-based conditioning: a comparison with conventional conditioning regimen.
Haematologica.2009;94:1312-5.
14) Lee SS et al. Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic
Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. Yonsei Med
J.2020;61:452-9.
15) Boztug H et al. Treosulfan-based conditioning regimens for allogeneic HSCT in children with
acute lymphoblastic leukaemia. Ann Hematol.2015;94:297-306.
16) Nagler A et al. Low-intensity conditioning is sufficient to ensure engraftment in matched
unrelated bone marrow transplantation. Exp Hematol.2001;29:362-70.
17) Resnick IB et al. Allogeneic stem cell transplantation for severe acquired aplastic anaemia using
a fludarabine-based preparative regimen. Br J Haematol.2006;133:649-54.
18) Slatter MA et al. Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell
Transplantation in Children with Primary Immunodeficiency: UK Experience. Biol Blood
Marrow Transplant.2018;24:529-36.
19) Güngör T et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell
transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
Lancet.2014;383:436-48.
20) Felber M, et al. Targeted busulfan-based reduced-intensity conditioning and HLA-matched
HSCT cure hemophagocytic lymphohistiocytosis. Blood Adv.2020;4:1998-2010.
21) Bartelink IH et al. Fludarabine and exposure-targeted busulfan compares favorably with
busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell
transplantation: maintaining efficacy with less toxicity. Biol Blood Marrow
Transplant.2014;20:345-53.
22) Wagner JE et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi
anemia. Blood.2007;109:2256-62.
23) Tanaka J et al. Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT
for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working
Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Bone Marrow
Transplant.2013;48:1389-94.
35
334 / 451
要望番号；IV-145
11) Spyridonidis A et al. Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for
Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the
Acute Leukemia Working Party of the EBMT. Hemasphere.2023;7:e812.
12) Srinivasan R et al. Overcoming graft rejection in heavily transfused and allo-immunised
patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell
transplantation. Br J Haematol.2006;133:305-14.
13) Maury S et al. Improved outcome of patients older than 30 years receiving HLA-identical
sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using
fludarabine-based conditioning: a comparison with conventional conditioning regimen.
Haematologica.2009;94:1312-5.
14) Lee SS et al. Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic
Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. Yonsei Med
J.2020;61:452-9.
15) Boztug H et al. Treosulfan-based conditioning regimens for allogeneic HSCT in children with
acute lymphoblastic leukaemia. Ann Hematol.2015;94:297-306.
16) Nagler A et al. Low-intensity conditioning is sufficient to ensure engraftment in matched
unrelated bone marrow transplantation. Exp Hematol.2001;29:362-70.
17) Resnick IB et al. Allogeneic stem cell transplantation for severe acquired aplastic anaemia using
a fludarabine-based preparative regimen. Br J Haematol.2006;133:649-54.
18) Slatter MA et al. Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell
Transplantation in Children with Primary Immunodeficiency: UK Experience. Biol Blood
Marrow Transplant.2018;24:529-36.
19) Güngör T et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell
transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
Lancet.2014;383:436-48.
20) Felber M, et al. Targeted busulfan-based reduced-intensity conditioning and HLA-matched
HSCT cure hemophagocytic lymphohistiocytosis. Blood Adv.2020;4:1998-2010.
21) Bartelink IH et al. Fludarabine and exposure-targeted busulfan compares favorably with
busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell
transplantation: maintaining efficacy with less toxicity. Biol Blood Marrow
Transplant.2014;20:345-53.
22) Wagner JE et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi
anemia. Blood.2007;109:2256-62.
23) Tanaka J et al. Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT
for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working
Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Bone Marrow
Transplant.2013;48:1389-94.
35
334 / 451